Alex Liu, Ph.D., graduated from Peking University, is an expert in the field of synthetic biology. He has years of deep experience in gene and cell therapy, leading R&D projects such as CAR-T cells and oncolytic viruses. In 2019, he founded Yixi Biotech., focusing on the biosynthesis of nutrients for humans and animals. Under his leadership, the company has spearheaded the modification of chassis microorganisms (e.g., E. coli) and the design of metabolic pathways, achieving breakthroughs in the industrial biosynthesis of nutrients including Human Milk Oligosaccharides (HMOs). In 2023, Yixi Biotechnology delivered China's first HMOs production line. By 2025, the company launched a production line expansion project, aiming to scale annual output from 300 tons to 3,000 tons. Once completed, this facility will become the world's largest single-site HMOs production plant.
FBIF specializes in turning "imagination" into "reality."Here, we will invite well-known domestic and international raw material companies to share laboratory samples of their latest ingredients over the course of two days, transforming these raw materials into products and ensuring that innovation goes beyond mere ideas and theories.
As an audience, you have the opportunity to taste, review, and share your impressions. Genuine exchanges within the industry are the driving force behind the continuous advancement of functional ingredients.